Crinetics Pharmaceuticals Inc. has reported parathyroid hormone PTH1 receptor antagonists potentially useful for the treatment of kidney stones, osteoporosis, cardiovascular disorders, cognitive disorders, primary hyperparathyroidism and secondary hyperparathyroidism.